{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012101","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2025-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.810539+00:00","generated_at":"2026-05-17T12:27:40.076923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Intelligent Bio Solutions Q4 revenue up 16% YoY to $844K; progress on FDA 510(k) for U.S. market","bullets":["Q4 FY2025 revenue $843,884 (+16% YoY); cartridge sales up 24% YoY.","Added 115 new accounts in FY2025; active base >450 across 24 countries with 18 distributors.","FDA 510(k) submission in progress for opiate test system; seeking U.S. clearance beyond Forensic Use Only.","Operational improvements: multilingual system, HubSpot CRM, new U.S. patent; accounting system upgrade underway.","Net loss or EPS not disclosed; company reports 'reduced net loss' but no specific figures."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012101","json":"https://secwatch.observer/filing/0001493152-25-012101.json","markdown":"https://secwatch.observer/filing/0001493152-25-012101.md","text":"https://secwatch.observer/filing/0001493152-25-012101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315225012101/0001493152-25-012101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315225012101/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:27:40.076923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}